Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00114283 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2015-04-15
Summary
This phase II trial studies how well lapatinib ditosylate works in treating patients with metastatic or recurrent head and neck cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- Recurrent Salivary Gland Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Recurrent Squamous Cell Carcinoma of the Oropharynx
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Verrucous Carcinoma of the Larynx
- Recurrent Verrucous Carcinoma of the Oral Cavity
- Salivary Gland Squamous Cell Carcinoma
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Stage IVA Salivary Gland Cancer
- Stage IVA Squamous Cell Carcinoma of the Larynx
- Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVA Squamous Cell Carcinoma of the Oropharynx
- Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVA Verrucous Carcinoma of the Larynx
- Stage IVA Verrucous Carcinoma of the Oral Cavity
- Stage IVB Salivary Gland Cancer
- Stage IVB Squamous Cell Carcinoma of the Larynx
- Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVB Verrucous Carcinoma of the Larynx
- Stage IVB Verrucous Carcinoma of the Oral Cavity
- Stage IVC Salivary Gland Cancer
- Stage IVC Squamous Cell Carcinoma of the Larynx
- Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IVC Squamous Cell Carcinoma of the Oropharynx
- Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVC Verrucous Carcinoma of the Larynx
- Stage IVC Verrucous Carcinoma of the Oral Cavity
- Tongue Cancer
Interventions
- DRUG
-
lapatinib ditosylate
Given PO
- OTHER
-
laboratory biomarker analysis
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Christopher Thomas · University of Virginia
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-03-31
- Primary Completion
- 2006-10-31
- Completion
- 2006-10-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
NCT00498953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05172258 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
NCT03010150 ·Status: RECRUITING
-
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
NCT00068497 ·Status: COMPLETED ·Phase: NA
-
Carboplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer
NCT00003206 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
NCT00055770 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT01316757 ·Status: COMPLETED ·Phase: PHASE2
-
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00095628 ·Status: COMPLETED ·Phase: PHASE2
-
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
NCT00095641 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01064479 ·Status: COMPLETED ·Phase: PHASE2
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00020189 ·Status: COMPLETED ·Phase: PHASE2
-
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00003443 ·Status: COMPLETED ·Phase: PHASE2
-
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT06636734 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00033618 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
NCT00014118 ·Status: COMPLETED ·Phase: PHASE2
-
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
NCT01195922 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
NCT04643379 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)
NCT03198130 ·Status: COMPLETED ·Phase: PHASE1
-
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630 ·Status: RECRUITING ·Phase: PHASE2
-
Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial
NCT04413214 ·Status: COMPLETED ·Phase: PHASE1